Skip to main content
Erschienen in: Pneumo News 5/2018

28.08.2018 | Tuberkulose | fortbildung

Mind the Gap!

Welt ohne Tuberkulose — warum die EndTB-Strategie der WHO so schwierig ist

verfasst von: Dr. med. Constanze Born, Prof. Dr. med. Dr. h.c. Christoph Lange, Dr. med. Jan Heyckendorf, Dr. med. Christian Herzmann, Dr. med. Gunar Günther, Hans-Peter Grobbel, Niklas Köhler, Juliane Radloff, Maja Reimann, MSc, Dr. med. Helmut J. F. Salzer, MPH, Dr. rer. nat. Patricia Sanchéz-Carballo, Dagmar Schaub, Dipl.-Ing.

Erschienen in: Pneumo News | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Mit 1,7 Mio. Todesfällen ist die Tuberkulose (TB) die häufigste Infektionskrankheit und weltweit eine der zehn häufigsten Todesursachen. Die EndTB-Strategie der WHO ist eine ehrgeizige Vision, die TB zu eliminieren. Obwohl das Hauptaugenmerk der Strategie in den Hochinzidenzländern liegt, sind auch Niedriginzidenzländer wie Deutschland mit 5.912 Fällen im Jahr 2016, z. B. aufgrund von Migrationsbewegungen, noch weit von diesem Ziel entfernt.
Literatur
1.
Zurück zum Zitat Global tuberculosis report 2017. World Health Organization, Genf, 2017. Licence: CC BY-NC-SA 3.0 IGO Global tuberculosis report 2017. World Health Organization, Genf, 2017. Licence: CC BY-NC-SA 3.0 IGO
2.
Zurück zum Zitat Robert Koch-Institut (RKI). Bericht zur Epidemiologie der Tuberkulose in Deutschland fur 2016. ISBN 978-3-89606-285-7 Robert Koch-Institut (RKI). Bericht zur Epidemiologie der Tuberkulose in Deutschland fur 2016. ISBN 978-3-89606-285-7
3.
Zurück zum Zitat Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research. An overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299–314CrossRefPubMed Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research. An overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299–314CrossRefPubMed
4.
Zurück zum Zitat Kaufmann SHE, Lange C, Rao M et al. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. Lancet Respir Med. 2014;2(4):301–20CrossRefPubMed Kaufmann SHE, Lange C, Rao M et al. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. Lancet Respir Med. 2014;2(4):301–20CrossRefPubMed
5.
Zurück zum Zitat Fine PE. Variation in protection by BCG. Implications of and for heterologous immunity. Lancet. 1995;346(8986):1339–45CrossRefPubMed Fine PE. Variation in protection by BCG. Implications of and for heterologous immunity. Lancet. 1995;346(8986):1339–45CrossRefPubMed
6.
Zurück zum Zitat Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil. The BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–5CrossRefPubMed Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil. The BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–5CrossRefPubMed
7.
Zurück zum Zitat Mangtani P, Abubakar I, Ariti C et al. Protection by BCG vaccine against tuberculosis. A systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80CrossRefPubMed Mangtani P, Abubakar I, Ariti C et al. Protection by BCG vaccine against tuberculosis. A systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80CrossRefPubMed
8.
Zurück zum Zitat Scriba TJ, Kaufmann SHE, Henri Lambert P et al. Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. J Infect Dis. 2016;214(5):659–64CrossRefPubMed Scriba TJ, Kaufmann SHE, Henri Lambert P et al. Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines. J Infect Dis. 2016;214(5):659–64CrossRefPubMed
9.
Zurück zum Zitat Loxton AG, Knaul JK, Grode L et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017;24(2); pii: e00439–16CrossRefPubMedPubMedCentral Loxton AG, Knaul JK, Grode L et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017;24(2); pii: e00439–16CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Gillard P, Yang PC, Danilovits M et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis. A phase II randomised study. Tuberculosis. 2016;100:118–27CrossRefPubMed Gillard P, Yang PC, Danilovits M et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis. A phase II randomised study. Tuberculosis. 2016;100:118–27CrossRefPubMed
11.
Zurück zum Zitat Clark S, Lanni F, Marinova D et al. Revaccination of Guinea Pigs with the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG‘es Protection Against Tuberculosis. J Infect Dis. 2017;216(5):525–33CrossRefPubMed Clark S, Lanni F, Marinova D et al. Revaccination of Guinea Pigs with the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG‘es Protection Against Tuberculosis. J Infect Dis. 2017;216(5):525–33CrossRefPubMed
12.
Zurück zum Zitat Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG. A randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8CrossRefPubMedPubMedCentral Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG. A randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Lange C, Mandalakas AM, Kalsdorf B et al. Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathog Immun. 2016;1(2):308–29CrossRefPubMedPubMedCentral Lange C, Mandalakas AM, Kalsdorf B et al. Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathog Immun. 2016;1(2):308–29CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Schaberg T, Bauer T, Brinkmann F et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie. 2017;71(6):325–97CrossRefPubMed Schaberg T, Bauer T, Brinkmann F et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie. 2017;71(6):325–97CrossRefPubMed
15.
Zurück zum Zitat Zak DE, Penn-Nicholson A, Scriba TJ et al. A blood RNA signature for tuberculosis disease risk. A prospective cohort study. Lancet. 2017;387(10035):2312–22CrossRef Zak DE, Penn-Nicholson A, Scriba TJ et al. A blood RNA signature for tuberculosis disease risk. A prospective cohort study. Lancet. 2017;387(10035):2312–22CrossRef
16.
Zurück zum Zitat Dowdy DW, Grant AD, Dheda K et al. Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. J Infect Dis. 2017;216(suppl_6):S654–61CrossRefPubMed Dowdy DW, Grant AD, Dheda K et al. Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis. J Infect Dis. 2017;216(suppl_6):S654–61CrossRefPubMed
17.
Zurück zum Zitat Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance. A prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2016;18(1):76–84CrossRef Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance. A prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2016;18(1):76–84CrossRef
18.
Zurück zum Zitat Jafari C, Olaru ID, Daduna F et al. Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. Eur Respir J. 2018;51(5); https://doi.org/10.1183/13993003.02189-2017 Jafari C, Olaru ID, Daduna F et al. Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. Eur Respir J. 2018;51(5); https://​doi.​org/​10.​1183/​13993003.​02189-2017
19.
Zurück zum Zitat Feiterna-Sperling C, Brinkmann F, Adamczick C et al. S2k-Leitlinie zur Diagnostik, Pravention und Therapie der Tuberkulose im Kindes- und Jugendalter. Pneumologie. 2017;71(10):629–80CrossRefPubMed Feiterna-Sperling C, Brinkmann F, Adamczick C et al. S2k-Leitlinie zur Diagnostik, Pravention und Therapie der Tuberkulose im Kindes- und Jugendalter. Pneumologie. 2017;71(10):629–80CrossRefPubMed
20.
Zurück zum Zitat Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV. A systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270CrossRefPubMedPubMedCentral Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV. A systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chamie G, Luetkemeyer A, Walusimbi-Nanteza M et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung. 2010;14(10):1295–302 Chamie G, Luetkemeyer A, Walusimbi-Nanteza M et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung. 2010;14(10):1295–302
22.
Zurück zum Zitat Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009; 30(4):797–810CrossRefPubMed Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009; 30(4):797–810CrossRefPubMed
24.
Zurück zum Zitat Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1):CD000171 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1):CD000171
25.
26.
Zurück zum Zitat Sharma A, Hill A, Kurbatova E et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa. A mathematical modelling study. Lancet Infect Dis. 2017; 7(7):707–15CrossRef Sharma A, Hill A, Kurbatova E et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa. A mathematical modelling study. Lancet Infect Dis. 2017; 7(7):707–15CrossRef
27.
Zurück zum Zitat Tiberi S, Du Plessis N, Walzl G et al. Tuberculosis. Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018; https://doi.org/10.1016/S1473-3099(18)30110-5 Tiberi S, Du Plessis N, Walzl G et al. Tuberculosis. Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018; https://​doi.​org/​10.​1016/​S1473-3099(18)30110-5
28.
Zurück zum Zitat Falzon D, Schunemann HJ, Harausz E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3); https://doi.org/10.1183/13993003.02308-2016 Falzon D, Schunemann HJ, Harausz E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3); https://​doi.​org/​10.​1183/​13993003.​02308-2016
29.
Zurück zum Zitat Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2014;190(4):374–83CrossRefPubMed Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2014;190(4):374–83CrossRefPubMed
30.
Zurück zum Zitat Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients with MDR-TB. J Antimicrob Chemother. 2016;71(4):852–55CrossRefPubMed Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients with MDR-TB. J Antimicrob Chemother. 2016;71(4):852–55CrossRefPubMed
31.
Zurück zum Zitat Carter DJ, Glaziou P, Lonnroth K et al. The impact of social protection and poverty elimination on global tuberculosis incidence. A statistical modelling analysis of Sustainable Development Goal 1. Lancet Global Health. 2018;6(5):e514–22CrossRefPubMed Carter DJ, Glaziou P, Lonnroth K et al. The impact of social protection and poverty elimination on global tuberculosis incidence. A statistical modelling analysis of Sustainable Development Goal 1. Lancet Global Health. 2018;6(5):e514–22CrossRefPubMed
32.
Zurück zum Zitat Murray M, Oxlade O, Lin HH. Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis. 2011;15Suppl 2:64–70CrossRefPubMed Murray M, Oxlade O, Lin HH. Modeling social, environmental and biological determinants of tuberculosis. Int J Tuberc Lung Dis. 2011;15Suppl 2:64–70CrossRefPubMed
33.
Zurück zum Zitat Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84CrossRefPubMedPubMedCentral Dorman SE, Schumacher SG, Alland D et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Liu F, Du FJ, Jia HY et al. Inadequate values from an interferon-gamma release assay for smear-negative tuberculosis in a high-burden setting. Int J Tuberc Lung Dis. 2014;18(12):1496-501 Liu F, Du FJ, Jia HY et al. Inadequate values from an interferon-gamma release assay for smear-negative tuberculosis in a high-burden setting. Int J Tuberc Lung Dis. 2014;18(12):1496-501
35.
Zurück zum Zitat http://www.pipelinereport.org URL /2017/tbtx; zugegriffen am 3.6.2018 http://www.pipelinereport.org URL /2017/tbtx; zugegriffen am 3.6.2018
Metadaten
Titel
Mind the Gap!
Welt ohne Tuberkulose — warum die EndTB-Strategie der WHO so schwierig ist
verfasst von
Dr. med. Constanze Born
Prof. Dr. med. Dr. h.c. Christoph Lange
Dr. med. Jan Heyckendorf
Dr. med. Christian Herzmann
Dr. med. Gunar Günther
Hans-Peter Grobbel
Niklas Köhler
Juliane Radloff
Maja Reimann, MSc
Dr. med. Helmut J. F. Salzer, MPH
Dr. rer. nat. Patricia Sanchéz-Carballo
Dagmar Schaub, Dipl.-Ing.
Publikationsdatum
28.08.2018
Verlag
Springer Medizin
Erschienen in
Pneumo News / Ausgabe 5/2018
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI
https://doi.org/10.1007/s15033-018-0980-1

Weitere Artikel der Ausgabe 5/2018

Pneumo News 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.